Past studies have shown that the prevalence of gestational diabetes mellitus (GDM) has been underestimated, and this can have major implications for healthcare planning. With the changes in diagnostic criteria for GDM, we wanted to assess the accuracy of the diagnosis in a private hospital setting. Using data from the hospital's obstetric database, medical records and a private pathology provider, we established the true prevalence of GDM and compared it with the NSW Perinatal Data Collection. The recorded prevalence of 6.8% was well below the real value of 15.0%.

No abstract

Optimising treatment for Australian melanoma patients can save taxpayers millions of dollars annuallyTO THE EDITOR: Patients with BRAF-mutated metastatic melanoma benefit greatly from the novel BRAF inhibitor dabrafenib and the checkpoint inhibitor ipilimumab, recently listed under the Australian Pharmaceutical Benefits Scheme (PBS). Dabrafenib results in rapid responses; but the cancer later adapts, and patients relapse rapidly. Conversely, ipilimumab slowly reactivates anticancer immunity, meaningfully improving long-term survival (up to around 20% at 5 years).

No abstract